Mereo BioPharma Group plc Sponsored ADR Stock News

BURLINGAME, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced an exclusive licensing agreement with Mereo BioPharma (NASDAQ: MREO) for vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2), a rare, debilitating bone disorder wi...

Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027  LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced it...

Mereo BioPharma Group plc's phase 3 ORBIT study for setrusumab in osteogenesis imperfecta will continue to final analysis, expected by end of 2025. The recent 35% MREO stock drop was due to not meeting early efficacy stopping criteria of ORBIT, not due to safety or trial failure. The ongoing phase 2/3 ORBIT study is targeting OI patients ages 5 to 25, while the phase 3 COSMIC trial is going aft...

Ultragenyx and Mereo stocks crashed Thursday after their treatment for brittle bone disease missed its mark in a second interim look.

Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the fi...

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025

Stocks priced under $10 present an attractive entry point into the market for investors seeking to maximize portfolio diversification and growth potential without a significant upfront capital outlay. These affordable equities allow investors to acquire a larger number of shares for a given investment and can yield substantial percentage gains.

LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025, at 8:40 am ET / 1:40 pm GMT.